How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/endometrial-hyperplasia-prevention.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Endometrial Hyperplasia Prevention — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endometrial Hyperplasia Prevention (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Endometrial Hyperplasia Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Endometrin	progesterone	Ferring	Progesterone [EPC]	Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Progesteron	Progesteron	Minia University		Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1
Depo-Provera	medroxyprogesterone	Pfizer	Progestin	Progesterone receptor	1959-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Ferring · 1 drug in Endometrial Hyperplasia Prevention
Minia University · 1 drug in Endometrial Hyperplasia Prevention
Pfizer · 1 drug in Endometrial Hyperplasia Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Endometrial Hyperplasia Prevention:

Cite this brief

Drug Landscape (2026). Endometrial Hyperplasia Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/endometrial-hyperplasia-prevention. Accessed 2026-06-10.

Endometrial Hyperplasia Prevention full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing